ReviewCancer cell2021
Targeting pan-essential genes in cancer: Challenges and opportunities.
Review in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 189 citations in OpenAlex.
- IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.The Journal of experimental medicine · 2023Trial
- Antitumor-Relevant Evaluation of Liquid and MicroencapsulatedMolecules (Basel, Switzerland) · 2026Article
- PARG Governs a PARylation-Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination-Mediated Chemoresistance.Cancer research · 2026Article
- Essential lncRNAs in the human transcriptome.Cell genomics · 2026Article
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Nine familial exterminations: Cas13d eliminates uveal melanoma cells through collateral RNA degradation.Molecular therapy. Oncology · 2026Article
- Article
- Pan-cancer atlas of ITGA6 unveils its multifaceted oncogenic roles and therapeutic potential in uveal melanoma.BMC cancer · 2026Article
- Flux sampling and graph neural networks for improved gene essentiality prediction in mammalian genome-scale metabolic models.NPJ systems biology and applications · 2026Article
- IRS4 is a PI3K-activating cancer dependency up-regulated through DNA rearrangements or epigenetic mechanisms in multiple solid tumors.Science advances · 2026Article
- Review
- FRAIL: fragment-based reinforcement learning for molecular design and benchmarking on fatty acid amide hydrolase 1 (FAAH-1).Molecular diversity · 2026Article
- Exploring the Role of GGA2 in Cancer Progression: Pan-Cancer Bioinformatics and Experimental Validation in Prostate Cancer.International journal of molecular sciences · 2026Article
- Hemizygous loss of helicases promotes genomic instability and cancer development.Science advances · 2026Article
- Targeting the HSP60/p53 Axis with Extracellular Vesicle-Delivered siRNA Reprograms Glycolysis in Prostate Cancer.International journal of biological sciences · 2026Article
- Synthetic lethality in cancer drug discovery: challenges and opportunities.Nature reviews. Drug discovery · 2026Review
- Analytical Techniques as Indicators of Biomarkers in Proteomics Cancer Diagnosis.Anti-cancer agents in medicinal chemistry · 2026Review
- Interplay between TGF-β signaling and long non-coding RNAs in digestive system cancers: mechanisms and biological implications.Human cell · 2025Review
- Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex.Cancer discovery · 2025Article
- Drug toxicity prediction based on genotype-phenotype differences between preclinical models and humans.EBioMedicine · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Despite remarkable successes in the clinic, cancer targeted therapy development remains challenging and the failure rate is disappointingly high. This problem is partly due to the misapplication of the targeted therapy paradigm to therapeutics targeting pan-essential genes, which can result in therapeutics whereby efficacy is attenuated by dose-limiting toxicity. Here we summarize the key features of successful chemotherapy and targeted therapy agents, and use case studies to outline recurrent challenges to drug development efforts targeting pan-essential genes. Finally, we suggest strategies to avoid previous pitfalls for ongoing and future development of pan-essential therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.